[Generation of a trans-complementable defective recombinant provirus and loading a transgene]

Area of Science:

• Molecular Biology
• Virology
• Gene Therapy

Context:

• Developing efficient and safe gene transfer methods is crucial for cancer therapy.
• Traditional viral vectors face challenges in specificity and immunogenicity.
• Non-viral methods often lack sufficient efficiency for therapeutic applications.

Purpose:

• To create a novel gene transfer system for tumor cells.
• To combine the benefits of non-viral gene transfer with recombinant retroviruses.
• To engineer a retroviral vector for targeted delivery of the Herpes Simplex Virus 1 thymidine kinase gene (HSV1-TK).

Summary:

• A modified Moloney murine leukemia provirus was engineered by replacing its env gene with the HSV1-TK gene.
• Transfection of this construct resulted in viral particles capable of encapsidating the transgene.
• The delivered HSV1-TK gene conferred sensitivity to ganciclovir, a prodrug activated by HSV1-TK into a toxic compound.
• Complementation with a retroviral envelope gene produced infectious viral particles that efficiently transduced HSV1-TK into tumor cells.

Impact:

• This system offers a promising approach for targeted gene therapy in cancer treatment.
• The engineered retroviral particles facilitate the delivery of therapeutic genes specifically to tumor cells.
• The ganciclovir-mediated cell killing provides a potential mechanism for tumor regression.